| P2093 | author name string | Suraj K George | |
| | P Kusumakumary | |
| | R Shiji | |
| | T T Sreelekha | |
| | Manjusha Nair | |
| | Alphy Rose-James | |
| P2860 | cites work | Isolation and expression of a complementary DNA that confers multidrug resistance | Q24295219 |
| | A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL | Q28254962 |
| | Biochemistry of multidrug resistance mediated by the multidrug transporter | Q29616476 |
| | The role of TEL fusion genes in pediatric leukemias | Q33537074 |
| | Childhood B-acute lymphoblastic leukemia: a genetic update | Q33777616 |
| | A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27 | Q34256192 |
| | The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias | Q34529043 |
| | Treatment of FLT3-ITD acute myeloid leukemia. | Q34636735 |
| | Cytogenetics and molecular genetics of acute lymphoblastic leukemia. | Q34797842 |
| | Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor | Q34997317 |
| | Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia | Q35084229 |
| | Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q35220417 |
| | Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study | Q36201257 |
| | FLT3 mutations: biology and treatment | Q36662153 |
| | Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study | Q37412290 |
| | The molecular biology of mixed lineage leukemia | Q37522825 |
| | TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. | Q38339292 |
| | The biochemistry of P-glycoprotein-mediated multidrug resistance | Q38364215 |
| | Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines | Q39260667 |
| | Biology and treatment of infant leukemias | Q40538534 |
| | Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia | Q40541692 |
| | TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia | Q40735765 |
| | The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials | Q41694396 |
| | FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION. | Q43188286 |
| | Therapeutic resistance: ALL-important mutations | Q43679021 |
| | FLT3 mutations in childhood acute lymphoblastic leukemia | Q44690047 |
| | Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia | Q46443538 |
| | Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. | Q50776368 |
| | Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. | Q53527272 |
| | Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. | Q54044443 |
| | Multidrug resistance is more than MDR1 activity | Q54168791 |
| | Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. | Q54242225 |
| | Acute Lymphoblastic Leukemia in Children. | Q55059361 |
| | Acute lymphoblastic leukaemia | Q56722375 |
| | E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features | Q60171404 |
| | Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease | Q73555805 |
| | Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q73631267 |
| | Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia | Q73851055 |
| | Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia | Q74576864 |
| | Acute lymphoblastic leukemia | Q77153499 |
| | Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells | Q78016517 |
| | Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia | Q80962315 |
| P433 | issue | 9 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| | lymphoblastic leukemia | Q18553852 |
| P304 | page(s) | 98 | |
| P577 | publication date | 2016-07-23 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine | |
| P478 | volume | 33 | |